Trius Therapeutics Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares for Common Stock Offering

Trius Therapeutics, Inc. TSRX today announced that the underwriters of its public offering that priced on January 26, 2012 have exercised in full their option to purchase an additional 1,290,000 shares of common stock. With the sale of the additional shares at a price to the public of $5.25 per share, the aggregate gross proceeds to Trius from this offering are expected to be approximately $51.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering, including the sale of the additional shares, is expected to close on or about January 31, 2012, subject to customary closing conditions.